RT @OphthTimes: . @REGENXBIO announces dosing of first patient in AAVIATE phase…
[ad_1]
RT @OphthTimes: . @REGENXBIO announces dosing of first patient in AAVIATE phase II trial of RGX-314 for treatment of wet AMD using suprac…
[ad_2]
Source by Thomas Ciulla, MD, MBA